Clinical Study to Evaluate the LensGen® Juvene® Intraocular Lens

NCT ID: NCT05364983

Last Updated: 2023-03-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-05-31

Study Completion Date

2026-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the safety and effectiveness of the Juvene® IOL for the treatment of aphakia and mitigation of the effects of presbyopia after removal of the natural crystalline lens due to cataract.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cataract Presbyopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

A prospective, randomized, controlled, double-masked, phased, multicenter clinical study
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers
The subject will be masked to randomization assignment and will be unmasked at the completion of the study. Scheduled masked postoperative assessments will be performed by a masked examiner

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Investigational IOL

Juvene® IOL

Group Type EXPERIMENTAL

Juvene IOL

Intervention Type DEVICE

Cataract extraction and implantation of a posterior chamber IOL

Control IOL

Tecnis® Monofocal (ZCB00, PCB00 or DCB00)

Group Type ACTIVE_COMPARATOR

Tecnis® Monofocal (ZCB00, PCB00 or DCB00)

Intervention Type DEVICE

Cataract extraction and implantation of a posterior chamber IOL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Juvene IOL

Cataract extraction and implantation of a posterior chamber IOL

Intervention Type DEVICE

Tecnis® Monofocal (ZCB00, PCB00 or DCB00)

Cataract extraction and implantation of a posterior chamber IOL

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects must be 22 years of age or older
* Able to comprehend and provide written informed consent
* Willing and able to comply with schedule for follow-up visits
* Demonstrate sufficient cognitive awareness to comply with examination procedures

Exclusion Criteria

* Subjects with clinically significant dry eye syndrome (DES) expected to impact postoperative visual acuity
* Subjects taking medications that may affect ocular function (including but not limited to mydriatic, cycloplegic and miotic agents; tricyclic antidepressants, phenothiazines, benzodiazepines, first generation antihistamines, and anticholinergic agents)
* Prior intraocular or corneal surgery (including corneal refractive correction i.e., LASIK, PRK, etc.)
* Any corneal dystrophy that may affect visual acuity (e.g., keratoconus, pellucid corneal degeneration, etc.)
Minimum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

LensGen, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Patrick R Casey, O.D.

Role: STUDY_DIRECTOR

LensGen, Inc.

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Patrick R Casey, O.D.

Role: CONTACT

(949) 472-5112

References

Explore related publications, articles, or registry entries linked to this study.

Garg S, De Jesus MT, Fletcher LM, Chayet A, Barragan E, Casey P. Twelve-month clinical outcomes after implantation of a new, modular, anterior shape-changing fluid optic intraocular lens. J Cataract Refract Surg. 2022 Oct 1;48(10):1134-1140. doi: 10.1097/j.jcrs.0000000000000935.

Reference Type BACKGROUND
PMID: 35297798 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://lensgen.com

Company website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CP20-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Evaluation of a Monofocal Intraocular Lens
NCT06428955 RECRUITING PHASE4
Evaluation of the Eyhance and Zoe Lenses
NCT06665659 NOT_YET_RECRUITING